WuXi Biologics (Cayman)
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of WuXi Biologics (Cayman) generated cash of $4,667,712,000, which is less than the previous year. Cash used in financing activities reached the amount of $1,961,163,000 last year. Net change in cash is therefore $3,274,617,000.
Cash Flow
| 2014 | 21.50M | -50.12M | 30.43M |
|---|---|---|---|
| 2015 | 107.15M | -336.21M | 377.4M |
| 2016 | 81.92M | -421.14M | 332.76M |
| 2017 | 360.28M | -2.21B | 2.22B |
| 2018 | 761.60M | -416.07M | 3.20B |
| 2019 | 1.20B | -4.49B | 5.41B |
| 2020 | 1.88B | -7.21B | 6.56B |
| 2021 | 3.43B | -9.60B | 8.20B |
| 2022 | 5.54B | -5.90B | -2.59B |
| 2023 | 4.66B | -3.22B | 1.96B |
WXXWY Cash Flow Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 6.39B | 9.00B | 7.09B | 6.20B | 4.08B | 503.88M | 169.10M | 158.22M | 5.94M | 4.17M |
Operating activities | ||||||||||
Net income | 3.39B | 4.42B | 3.38B | 1.68B | 1.01B | 630.59M | 252.62M | 141.09M | 65.40M | 49.01M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 1.16B | 800.67M | 481.78M | 303.00M | 221.36M | 141.53M | 87.47M | 93.18M | 57.00M | 42.30M |
Stock-based compensation expense | 1.27B | 1.23B | 531.92M | 276.37M | 203.93M | 128.37M | 65.07M | 47.64M | 26.86M | 4.76M |
| Deferred income tax benefit | 1.27B | 1.23B | 531.92M | 276.37M | 203.93M | 128.37M | 65.07M | 47.64M | 26.86M | 4.76M |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | -1.03B | -1.49B | -1.44B | -1.40B | -649.52M | -463.58M | -203.07M | -142.23M | -290.45M | -321.47M |
Inventories | 442.46M | -498.12M | -783.18M | -704.52M | -94.00M | -95.68M | -103.64M | -51.14M | -101.15M | -38.39M |
Accounts payable | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 290.45M | 321.47M |
Cash generated by operating activities | 4.66B | 5.54B | 3.43B | 1.88B | 1.20B | 761.60M | 360.28M | 81.92M | 107.15M | 21.50M |
Investing activities | ||||||||||
Purchases Of Investments | -15.08B | -10.77B | -59.30B | -20.35B | -4.64B | -1.05B | -2.82B | 0 | 0 | 0 |
Investments In Property Plant And Equipment | -4.04B | -5.86B | -6.50B | -6.02B | -3.21B | -1.34B | -670.60M | -428.88M | -334.36M | -51.04M |
Acquisitions Net | 0 | -131.48M | -2.53B | -155.23M | -300.82M | -1.27B | 1.54B | 0 | 0 | 0 |
Cash generated by investing activities | -3.22B | -5.90B | -9.60B | -7.21B | -4.49B | -416.07M | -2.21B | -421.14M | -336.21M | -50.12M |
Financing activities | ||||||||||
Common Stock Issued | 26.15M | 36.18M | 11.03B | 5.64B | 3.59B | 3.22B | 3.57B | 0 | 0 | 24M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -18.05M | 0 |
Repurchases of common stock | -916.91M | -2.80B | -2.51B | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | -818.45M | -295.01M | -822.11M | -349.85M | 1.90B | 0 | -902.9M | -24.68M | 400.48M | -4.42M |
Cash used in financing activities | 1.96B | -2.59B | 8.20B | 6.56B | 5.41B | 3.20B | 2.22B | 332.76M | 377.4M | 30.43M |
Net Change In Cash | 3.27B | -2.60B | 1.90B | 890.23M | 2.12B | 3.58B | 334.77M | 10.87M | 152.28M | 1.77M |
Cash at end of period | 9.66B | 6.39B | 9.00B | 7.09B | 6.20B | 4.08B | 503.88M | 169.10M | 158.22M | 5.94M |